Advisor to Active ETFs - Tweets, Retweets, Likes are not a recommendation, advice or a solicitation of any security. For ETF info: advisorshares.com #MSOGang
The investment landscape surrounding psychedelic medicine bears little resemblance to the one that emerged during the sector's first wave of public-market enthusiasm. Early interest brought capital
Summer is here, and with it comes the familiar hum of air conditioners running around the clock. From the sweltering streets of Phoenix to heat-stricken Paris, the global demand for cooling has never
Forget Buybacks. "Float Shrink" Is the Metric That Actually Matters. Every few months, a headline drops: "Apple Announces $90 Billion Buyback!" Wall Street cheers. Retail investors pile in. The stock
Rescheduling changes how cannabis is classified, but it does not yet fully change how the financial system interacts with it. Adult-use cannabis remains a Schedule I substance. As a result, Bank
Rescheduling has direct implications for federal taxation. Under Schedule I, cannabis operators have been subject to Section 280E of the Internal Revenue Code. That provision disallows deductions for
Federal policy has been a primary constraint on the U.S. cannabis industry. On April 23, 2026, Acting Attorney General Todd Blanche signed a final order transferring FDA-approved cannabis products and
A recent executive order from the White House marks a notable shift in how the federal government approaches psychedelic medicine, moving the category further into mainstream policy discussion and
The investing world is filled with erudite portfolio managers trying to dazzle investors with complex strategies as part of their marketing. CWS takes a different investing approach by "keeping it
Many investors are familiar with the concept of diversification, which involves making sure a portfolio isn't over-reliant on just a single stock or a single theme. This approach includes investing
Businesses in a wide variety of industries are stockpiling and battening down the hatches as the latest round of U.S. trade tariffs threaten to drive up costs, delay supply chains, and create